Sumitomo Pharma America (formerly Sunvion) has said that its ulotaront (SEP-363856), a novel trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, was unable to ...

A sweetened offer from Sumitomo Pharma has convinced endocrinology specialist Myovant to agree to a takeover, after its first was rejected. Sumitomo and its subsidiary Sumitovant Biopharma ...

The affected companies are Novartis Pharmaceuticals Corporation, Bayer Corporation, AbbVie, Regeneron Pharmaceuticals, ...

Thomas Kuhn, Chief Executive Officer of Poxel, stated: "As our exclusive discussions to monetize royalties from sales of ...

The Japanese stock market is trading modestly higher on Monday, adding to the gains in the previous session. The benchmark S&P/ASX ...

(RTTNews) - Reversing the losses in the previous session, the Japanese market is significantly higher on Thursday, following the broadly positive cues from global markets overnight. The Nikkei 225 is ...

Sumitomo Pharma was founded in 1897 and operates in Osaka, Japan. The company engages in the sector 'Pharmaceuticals, Medicinal Chemical & Botanical Products' (ISIC: 2100). This industry belongs ...

On Friday, JPMorgan (NYSE:JPM) adjusted its stance on Sumitomo Pharma (4506:JP) (OTC: DNPUF) stock, upgrading it from Underweight to Neutral. Accompanying this change in rating, the firm also doubled ...

Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally.

No identified affiliates for Sumitomo Dainippon Pharma in the 2024 election cycle. Contributions to 527s are not included in the Individuals, PACs, Soft (Indivs), or Soft (Orgs) columns, so the sum of ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...